GlassScriptPhysician profile
Kevin A Carter
NPI 1053403329
$49,123.01
in general payments reported to CMS, 2019-2025
33 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
See the full distribution for Sleep Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $11K · 2021: $6,145 · 2022: $2,560 · 2023: $477 · 2024: $733 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.85 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $45,540.03 | 2019-2025 | |
| Inspire Medical Systems, INC. | $886.42 | 2022-2025 | Inspire |
| Abbvie INC. | $364.59 | 2021-2022 | |
| Pfizer INC. | $262.13 | 2019-2021 | |
| Novo Nordisk INC | $223.46 | 2019-2022 | |
| Harmony Biosciences LLC | $219.21 | 2020-2024 | Wakix |
| Merck Sharp & Dohme LLC | $172.54 | 2019-2023 | Belsomra |
| Lilly USA, LLC | $145.36 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $136.77 | 2023 | Ingrezza |
| Amarin Pharma, INC. | $133.30 | 2019-2022 | |
| Axsome Therapeutics, INC. | $126.35 | 2022-2024 | Sunosi |
| Idorsia Pharmaceuticals US INC | $114.45 | 2022-2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.17 | 2020-2022 | |
| Amgen INC. | $95.63 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $85.28 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $76.44 | 2020 | |
| Glaxosmithkline, LLC. | $61.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.77 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $45.19 | 2024 | Lumryz |
| Biohaven Pharmaceutical Holding Company LTD. | $42.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.26 | 2021 | |
| Fisher & Paykel Healthcare INC | $27.65 | 2024 | Fisher & Paykel Healthcare |
| Eisai INC. | $19.36 | 2021 | |
| Esperion Therapeutics, INC. | $16.86 | 2021 | |
| Resmed Corp | $16.77 | 2023 | |
| Nestle Healthcare Nutrition INC. | $16.39 | 2021 | |
| Abbott Laboratories | $15.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2019 | |
| Itamar Medical INC | $14.55 | 2023 | Watchpatone |
| Kowa Pharmaceuticals America, INC. | $13.64 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.21 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.90 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.